{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:47:48Z","timestamp":1787737668863,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007634","name":"AU Optronics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euo.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:11:54Z","timestamp":1772082714000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT)"],"prefix":"10.1016","author":[{"given":"Sebastian C.","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-2595","authenticated-orcid":false,"given":"Matthias","family":"Jahnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florestan","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Wieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Flentje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Lewerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.019_b0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2026.02.019_b0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.02.019_b0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1078-1439(98)00002-7","article-title":"Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer","volume":"3","author":"Marini","year":"1997","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy","volume":"199","author":"Zargar","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.019_b0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.019_b0040","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.02.019_b0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"10.1016\/j.euo.2026.02.019_b0050","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO trial: a randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.euo.2026.02.019_b0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0060","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.019_b0065","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"Rodel","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2019.12.005","article-title":"The impact of radiation therapy on innate and adaptive tumor immunity","volume":"30","author":"Brandmaier","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0075","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.euo.2026.02.019_b0080","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euo.2026.02.019_b0085","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2026.02.019_b0090","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2026.02.019_b0095","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.019_b0100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.urolonc.2022.10.009","article-title":"Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: a systematic review and meta-analysis","volume":"41","author":"Maisch","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-019-6503-6","article-title":"Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer\u2014study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)","volume":"20","author":"Schmid","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2026.02.019_b0115","unstructured":"1 S-LH. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 0, AWMF-Registrierungsnummer 032\/038OL. Leitlinienprogramm Onkologie. (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 1."},{"key":"10.1016\/j.euo.2026.02.019_b0120","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1016\/j.annonc.2024.08.2328","article-title":"LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2026.02.019_b0125","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2026.02.019_b0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0135","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.02.019_b0145","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0022-5347(05)65074-4","article-title":"Analysis of early complications after radical cystectomy: results of a collaborative care pathway","volume":"167","author":"Chang","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.019_b0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/iju.12232","article-title":"Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy","volume":"21","author":"Roghmann","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2026.02.019_b0155","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.juro.2017.08.095","article-title":"Fistulous complications following radical cystectomy for bladder cancer: analysis of a large modern cohort","volume":"199","author":"Smith","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.02.019_b0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.euf.2023.05.002","article-title":"Complications after radical cystectomy: a systematic review and meta-analysis of randomized controlled trials with a meta-regression analysis","volume":"9","author":"Katsimperis","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.02.019_b0165","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clon.2021.03.023","article-title":"Image-guided adaptive radiotherapy for bladder cancer","volume":"33","author":"Kong","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.euo.2026.02.019_b0170","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.019_b0175","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.02.019_b0180","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002307","article-title":"Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances","volume":"6","author":"Jang","year":"2025","journal-title":"Explor Target Antitumor Ther"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:23:30Z","timestamp":1774056210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S2588931126000568"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.019","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT)","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}